Note 8 — Inventories

Inventories were written off as of March 31, 2026 due to shelf life limitations. Inventories at March 31, 2025 consisted of raw materials and work-in-progress that consist of chemicals and compounds used in our development of ViraxImmune™. Finished goods inventories, which were written off to research and development costs, consists of ViraxClear and ViraxVet test kits stored in a warehouse operated by a third party and were written down due to the expiration of the products. During the years ended March 31, 2026, 2025 and 2024, inventories expensed to cost of revenue were $4,733, $59,398, and $105,829, respectively.